Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products

Dachun Yao1, Michael Brownlee

  • 1Department of Medicine, Diabetes Research Center, Albert Einstein College of Medicine, Bronx, New York, USA.

Diabetes
|October 17, 2009
PubMed
Abstract

Insights

High glucose increases receptor for advanced glycation end products (RAGE) and its ligands via reactive oxygen species (ROS). Glyoxalase 1 (GLO1) mitigates this effect, suggesting a therapeutic target for diabetic complications.

Area of Science:

  • Endocrinology and Metabolism
  • Cell Biology
  • Molecular Biology

Background:

  • Receptor for advanced glycation end products (RAGE) interacts with ligands like S100 calgranulins and high mobility group box 1 (HMGB1) to promote inflammation.
  • Hyperglycemia-induced reactive oxygen species (ROS) are implicated in diabetic tissue damage pathways.

Purpose of the Study:

  • To evaluate the impact of hyperglycemia-induced ROS on RAGE and RAGE ligand expression.
  • To investigate the role of glyoxalase 1 (GLO1) in mediating these effects.

Main Methods:

  • Assessed expression of RAGE, S100A8, S100A12, and HMGB1 in human aortic endothelial cells (HAECs) under varying glucose conditions and gene manipulations (UCP1, SOD2, GLO1, NF-kappaB p65, AP-1).
  • Utilized chromatin immunoprecipitation (ChIP) to examine transcription factor binding.
  • Evaluated expression in mouse models of diabetes treated with a superoxide dismutase mimetic (MnTBAP).

Main Results:

  • High glucose significantly increased RAGE, S100A8, S100A12, and HMGB1 expression, an effect reversed by UCP1, SOD2, or GLO1 overexpression.
  • GLO1 knockdown mimicked high glucose effects; GLO1 overexpression in high glucose normalized NF-kappaB p65 and AP-1 binding.
  • Diabetes increased RAGE, S100A8, and HMGB1 expression, which was normalized by MnTBAP treatment.

Conclusions:

  • Hyperglycemia-driven ROS production elevates RAGE and RAGE ligand expression.
  • Methylglyoxal, a substrate of GLO1, mediates this ROS-induced increase, highlighting GLO1 as a key regulator.

Related Concept Videos

GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...